Orexo AB
STO:ORX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Orexo AB
STO:ORX
|
SE |
|
Mortgage Advice Bureau (Holdings) PLC
LSE:MAB1
|
UK |
Multiples-Based Value
The
Multiples-Based Value for
Orexo AB (ORX)
under the Base Case is
1.66
SEK.
Compared with the current market price of 20.95 SEK, the stock appears
Overvalued by 92%.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
ORX Competitors Multiples
Orexo AB Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| SE |
|
Orexo AB
STO:ORX
|
722.9m SEK | 27.8 | 1.1 | -1 | -0.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
887.6B USD | 13.5 | 42.6 | 28.7 | 30.6 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
574.2B USD | 6.1 | 21.4 | 14.9 | 18.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.5 | 11.6 | 13 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
232.5B GBP | 5.2 | 30.1 | 16.6 | 23.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
300.5B USD | 4.6 | 16.3 | 10.1 | 12.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
233.6B CHF | 5.2 | 20.8 | 12.9 | 16.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.4 | 7.7 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.1B USD | 2.5 | 20 | 7.7 | 10.2 | |
| UK |
|
GlaxoSmithKline PLC
LSE:GSK
|
88.4B GBP | 2.7 | 15.5 | 8.4 | 10.4 |